Ipca Laboratories Ltd

IPCALAB

Company Profile

  • Business description

    Ipca Laboratories Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company is an integrated pharmaceutical company manufacturing and marketing over 350 formulations and various API's covering various therapeutic segments. The company's API products include Atenolol (anti-hypertensive), Chloroquine Phosphate (anti-malarial), Chlorthalidone (diuretic), Furosemide (diuretic), Hydroxychloroquine Sulphate (DMARD), and Losartan. The company has only one reportable primary business segment, pharmaceuticals. Geographically, the maximum revenue is derived from outside India, mainly from Europe, Africa, the Americas, Asia, etc.

  • Contact

    125, Kandivli Industrial Estate
    Kandivli (West)
    MumbaiMH400067
    IND

    T: +91 2262105000

    https://www.ipca.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 March 2027

    Employees

    23,467

Stocks News & Analysis

stocks

Avoid these overvalued ASX shares

The two shares with the highest price to fair value in our Australian coverage.
stocks

Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?

Watching AI monetization, capex’s impact on margins, and guidance on Azure.
stocks

Lithium’s latest drop and what it means for ASX investors

Volatility returns to the lithium market.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,013.1022.900.25%
CAC 408,363.1423.030.28%
DAX 4025,011.35164.660.66%
Dow JONES (US)52,224.64385.380.74%
FTSE 10010,585.9161.150.58%
HKSE24,975.99156.30-0.62%
NASDAQ25,837.21329.131.29%
Nikkei 22567,511.121,278.931.93%
NZX 50 Index13,718.0161.980.45%
S&P 5007,509.2065.920.89%
S&P/ASX 2008,830.2023.700.27%
SSE Composite Index3,880.1315.760.41%

Market Movers